Frontiers in Oncology (Nov 2024)

Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital

  • Pilar Sotoca Rubio,
  • Ana María Barrill Corpa,
  • Víctor Alia Navarro,
  • Patricia Pérez de Aguado Rodríguez,
  • Jaime Moreno Doval,
  • Juan Carlos Calvo Pérez,
  • Patricia Guerrero Serrano,
  • Carlos García Merino,
  • Coral García de Quevedo Suero,
  • Jorge Fernández-Fradejas,
  • Juan José Serrano Domingo,
  • Íñigo Martínez Delfrade,
  • Blanca Isabel Morón García,
  • María Reyes Ferreiro Monteagudo,
  • Belén de Frutos González

DOI
https://doi.org/10.3389/fonc.2024.1446945
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionRegorafenib is indicated as treatment in third-line and beyond in patients with metastatic colorectal cancer.Methods This is a retrospective study of a cohort of patients with mCRC treated with regorafenib in Hospital Universitario Ramón y Cajal, in Madrid, Spain.ResultsWith the aim to assess the efficacy and safety of regorafenib, 91 patients treated between 2013 and 2023 were included. Only 1.1% of patients achieved disease control. Median progression free survival was 2.40 months and median overall survival was 4.76 months. The most frequent adverse events were fatigue and hand-foot skin reaction (59.34% and 28.57%, respectively).DiscussionOur results confirm the safety of regorafenib as treatment of mCRC in real clinical practice. Although our population is less pretreated than in the CORRECT trial, our disease control rate was inferior. This difference may be due to a worse baseline status and a high percentage of hepatic disease showed in our patients.

Keywords